Bone Marrow Stromal Cells Enhance Differentiation of Acute Myeloid Leukemia Induced by Pyrimidine Synthesis Inhibitors

Overview

Journal Am J Physiol Cell Physiol

Publisher American Physiological Society

Specialties Cell Biology
Physiology

Date 2024 Sep 16

PMID 39279497

Authors

Tomislav Smoljo

Hrvoje Lalic

Vilma Dembitz

Barbara Tomic

Josip Batinic

Radovan Vrhovac

Antonio Bedalov

Dora Visnjic

Affiliations

Soon will be listed here.

Abstract

Acute myeloid leukemia (AML) is a heterogeneous group of hematological malignancies characterized by differentiation arrest, high relapse rates, and poor survival. The bone marrow (BM) microenvironment is recognized as a critical mediator of drug resistance and a primary site responsible for AML relapse. Our previous study reported that 5-aminoimidazole-4-carboxamide ribonucleoside (AICAr) induces AML cell differentiation by inhibiting pyrimidine synthesis and activating Checkpoint kinase 1. Although the protective effect of BM stroma on leukemia cells in response to cytotoxic drugs is well-documented, its effect on AML differentiation remains less explored. In this study, we investigated the impact of stromal cell lines and primary mesenchymal stromal cells (MSCs) on AML cell line differentiation triggered by AICAr and brequinar, a known dihydroorotate dehydrogenase (DHODH) inhibitor. Our findings indicate that the mouse MS-5 stromal cell line, known for its cytoprotective effects, does not inhibit AML cell differentiation induced by pyrimidine synthesis inhibitors. Interestingly, AICAr caused morphological changes and growth arrest in MS-5 stromal cells via an AMP-activated protein kinase (AMPK)-dependent pathway. Human stromal cell lines HS-5 and HS-27, as well as primary MSCs isolated from patient bone marrow, were superior in promoting AML differentiation compared with mouse cells in response to AICAr and brequinar, with the inhibitors not significantly affecting the stromal cells themselves. In conclusion, our study highlights the supportive role of human BM MSCs in enhancing the differentiation effects of pyrimidine synthesis inhibitors on AML cells, suggesting that AML treatment strategies focusing on differentiation rather than cell killing may be successful in clinical settings. This study is the first to demonstrate that human stromal cell lines and primary mesenchymal stromal cells from patients enhance the in vitro differentiation of acute myeloid leukemia (AML) cells induced by pyrimidine synthesis inhibitors, 5-aminoimidazole-4-carboxamide ribonucleoside (AICAr), and brequinar. Furthermore, this is the first report to show that AICAr affects mouse bone marrow stromal cells by activating AMP-activated protein kinase (AMPK) and that human stromal cells are superior to mouse cells for testing the effects of drugs on AML differentiation.

References

Visnjic D, Lalic H, Dembitz V, Tomic B, Smoljo T . AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review. Cells. 2021; 10(5). PMC: 8147799. DOI: 10.3390/cells10051095. View

Huang J, Basu S, Zhao X, Chien S, Fang M, Oehler V . Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration. Blood Cancer J. 2015; 5:e302. PMC: 4450324. DOI: 10.1038/bcj.2015.17. View

Moschoi R, Imbert V, Nebout M, Chiche J, Mary D, Prebet T . Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. Blood. 2016; 128(2):253-64. DOI: 10.1182/blood-2015-07-655860. View

Yu S, Ye J, Wang Y, Lu T, Liu Y, Liu N . DNA damage to bone marrow stromal cells by antileukemia drugs induces chemoresistance in acute myeloid leukemia via paracrine FGF10-FGFR2 signaling. J Biol Chem. 2022; 299(1):102787. PMC: 9860495. DOI: 10.1016/j.jbc.2022.102787. View

Ghiraldeli L, Anderson R, Pladna K, Pardee T . Adenosine Monophosphate Activated Protein Kinase (AMPK) enhances chemotherapy response in Acute Myeloid Leukemia (AML). Cancer Lett. 2022; 535:215659. PMC: 9059102. DOI: 10.1016/j.canlet.2022.215659. View

Sykes D, Kfoury Y, Mercier F, Wawer M, Law J, Haynes M . Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. Cell. 2016; 167(1):171-186.e15. PMC: 7360335. DOI: 10.1016/j.cell.2016.08.057. View

Konopleva M, Konoplev S, Hu W, Zaritskey A, Afanasiev B, Andreeff M . Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 2002; 16(9):1713-24. DOI: 10.1038/sj.leu.2402608. View

Boyd A, Reid J, Salci K, Aslostovar L, Benoit Y, Shapovalova Z . Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche. Nat Cell Biol. 2017; 19(11):1336-1347. DOI: 10.1038/ncb3625. View

Dembitz V, Lalic H, Tomic B, Smoljo T, Batinic J, Dubravcic K . All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16. Int J Hematol. 2021; 115(1):43-53. DOI: 10.1007/s12185-021-03224-5. View

10.

Wang H, He X, Zhang L, Dong H, Huang F, Xian J . Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade. Blood. 2022; 139(26):3752-3770. PMC: 9247363. DOI: 10.1182/blood.2021015108. View

11.

Hawley S, Ross F, Russell F, Atrih A, Lamont D, Grahame Hardie D . Mechanism of Activation of AMPK by Cordycepin. Cell Chem Biol. 2020; 27(2):214-222.e4. PMC: 7031697. DOI: 10.1016/j.chembiol.2020.01.004. View

12.

Smoljo T, Tomic B, Lalic H, Dembitz V, Batinic J, Bedalov A . Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia. Front Pharmacol. 2023; 14:1258151. PMC: 10637411. DOI: 10.3389/fphar.2023.1258151. View

13.

Adamo A, Delfino P, Gatti A, Bonato A, Takam Kamga P, Bazzoni R . HS-5 and HS-27A Stromal Cell Lines to Study Bone Marrow Mesenchymal Stromal Cell-Mediated Support to Cancer Development. Front Cell Dev Biol. 2020; 8:584232. PMC: 7674674. DOI: 10.3389/fcell.2020.584232. View

14.

Zhou J, Yiying Quah J, Ng Y, Chooi J, Toh S, Lin B . ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. Haematologica. 2020; 105(9):2286-2297. PMC: 7556493. DOI: 10.3324/haematol.2019.230482. View

15.

Chen K, Hsu H, Lee C, Yen T, Ko Y, Yang C . The AMPK agonist AICAR inhibits TGF-β1 induced activation of kidney myofibroblasts. PLoS One. 2014; 9(9):e106554. PMC: 4154690. DOI: 10.1371/journal.pone.0106554. View

16.

Pilling D, Fan T, Huang D, Kaul B, Gomer R . Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS One. 2009; 4(10):e7475. PMC: 2759556. DOI: 10.1371/journal.pone.0007475. View

17.

Thomas C, Meade J, Holmes E . Aminoimidazole carboxamide ribonucleoside toxicity: a model for study of pyrimidine starvation. J Cell Physiol. 1981; 107(3):335-44. DOI: 10.1002/jcp.1041070305. View

18.

Madan V, Koeffler H . Differentiation therapy of myeloid leukemia: four decades of development. Haematologica. 2020; 106(1):26-38. PMC: 7776344. DOI: 10.3324/haematol.2020.262121. View

19.

Salminen A . The plasticity of fibroblasts: A forgotten player in the aging process. Ageing Res Rev. 2023; 89:101995. DOI: 10.1016/j.arr.2023.101995. View

20.

Foretz M, Guigas B, Viollet B . Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023; 19(8):460-476. PMC: 10153049. DOI: 10.1038/s41574-023-00833-4. View